Search results
May 13, 2024 · Hummingbird Bioscience is leading a bold new way of engineering biotherapeutics that can define the future of precision medicine. Building on our deep experience in biologics discovery and development, coupled with our proprietary linker-payload technologies, we are developing a pipeline of next-generation antibody-based therapeutics ...
We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.
Apr 25, 2024 · This gives HMBD-001 a novel mechanism of action for inhibiting tumor growth and drug resistance in HER3-driven cancers. Preclinical models have shown that HMBD-001 potently inhibits the activation of the MAPK/PI3K signaling pathway – and consequently, prevents tumor growth and drug resistance. References: 1. https://www.ncbi.nlm.nih.
Sep 24, 2022 · SINGAPORE - Singapore-based biomedical start-up Hummingbird Bioscience, which specialises in developing antibodies for cancer treatment, on Friday launched a new facility to expand its...
Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model...
Sep 23, 2022 · The latest addition to Singapore's growing biotech scene is Hummingbird Bioscience - a 40,000 sq ft, multimillion-dollar facility that looks into treatments for hard-to-treat diseases like...
Dec 6, 2021 · HMBD-001 is a clinical-stage IgG1 antibody designed to target HER3. Discovered using our proprietary RAD platform, HMBD-001 is now in development for the treatment of multiple solid tumors.
May 18, 2021 · Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and rich pipeline of clinical assets in global development.
Hummingbird. Hummingbird has come a long way since you started in 2015. The team has now grown into 150 strong, responsible for the full range of drug discovery and development activities. You are now a leading start-up in the field of precision biotherapeutics for cancer and autoimmune diseases.
When you join Hummingbird Bioscience, you join a passionate team rising to some of the biggest challenges in science to engineer and develop next-generation therapies for a new world of precision medicine.
